The PBS listing of Epidyolex is promising for Australian pharmaceutical cannabinoid developers also pursuing drug registration.

In a historic first, a medicinal cannabis drug has been listed on Australia’s Pharmaceutical Benefits Scheme (PBS), enabling Australians living with Dravet syndrome access to treatment for the rare form of epilepsy.

Federal health minister Greg Hunt announced last Friday that Epidyolex would be subsidised on the scheme from 1 May.

Epidyolex is pure cannabidiol (CBD) oil that has been shown to be effective in treating seizures associated with Dravet syndrome that presents within the first year of life in otherwise healthy infants. The treatment, which is considered highly beneficial to preventing seizures in children, can cost up to $24,000 per annum but patients will now pay $41.30…

Read Full Article Here